In-Hope: IN-HOspital Program to systematizE Chest Pain Protocol (IN-HOPE)

Sponsor
Hospital Samaritano Paulista (Other)
Overall Status
Completed
CT.gov ID
NCT04756362
Collaborator
Roche Diagnostics (Industry)
5,497
1
24.2
226.7

Study Details

Study Description

Brief Summary

Multicenter Nationwide Study for Analysis of the Potential Impact in Clinical Practice of Early Exclusion Protocols for Acute Myocardial Infarction with High Sensitivity Troponin T

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Chest pain is the main clinical complaint in emergency room visits and represents the most common symptom of Acute Myocardial Infarction, which is the main cause of death in Brazil and worldwide. Although most patients with chest pain do not have a final diagnosis of AMI, they remain under observation until the diagnosis of AMI is excluded. The most current strategy recommended for rapid AMI exclusion uses high-sensitivity cardiac troponin T at time zero and one hour later. However, some points that have not yet been properly evaluated in previous studies can be evaluated in the current study:

    • Evaluation of the early exclusion protocol (0 -1 hour) in a Brazilian population

    • Evaluation of the early exclusion protocol (0 -1 hour) in isolation and associated with traditional risk scores (TIMI, GRACE, HEART and EDACS)

    • Systematic evaluation of the early exclusion protocol (0 -1 hour) in patients without chest pain but with a pre-defined condition of suspected AMI

    • Evaluation of the prognostic value of an isolated high-sensitivity cardiac troponin T < 5 ng/L in a diverse population.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    5497 participants
    Observational Model:
    Cohort
    Time Perspective:
    Other
    Official Title:
    Potential Impact in Clinical Practice of Early Exclusion Protocols for Acute Myocardial Infarction With High Sensitivity Troponin T in Different Scenarios (IN-HOspital Program to SystematizE Chest Pain Protocol-IN HOPE)
    Actual Study Start Date :
    Jul 23, 2020
    Actual Primary Completion Date :
    Jan 31, 2022
    Actual Study Completion Date :
    Jul 31, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Prospective cohort

    A minimum of 294 patients will be included in the evaluation of 0 and 1 hour protocol (prospective evaluation).

    Retrospective cohort

    A minimum of 1,000 patients will be included in the evaluation of prognostic value of high sensitive cardiac troponin < 5 ng/L(retrospective evaluation).

    Outcome Measures

    Primary Outcome Measures

    1. Accuracy of early rule out for myocardial infarction diagnosis [30 days]

      Accuracy of the 0 and 1 hour algorithm using troponin for diagnosis of myocardial infarction compared to the gold standard with measurements every 3 hours

    Secondary Outcome Measures

    1. Accuracy of early rule out for myocardial infarction according to type of symptoms [30 days]

      Accuracy of the 0 and 1 hour algorithm using troponin for diagnosis of myocardial infarction compared to the gold standard with measurements every 3 hours with or without chest pain

    2. Accuracy of early rule out for myocardial infarction according to chest pain score (TIMI) [30 days]

      Accuracy of the 0 and 1 hour algorithm using troponin for diagnosis of myocardial infarction compared to the gold standard with measurements every 3 hours according to chest pain score (TIMI). TIMI score minimum 0 and maximum 7 points (higher scores mean a worse outcome).

    3. Accuracy of early rule out for myocardial infarction according to chest pain score (EDACS) [30 days]

      Accuracy of the 0 and 1 hour algorithm using troponin for diagnosis of myocardial infarction compared to the gold standard with measurements every 3 hours according to chest pain score (EDACS). EDACS score minimum -6 and maximum +20 points (higher scores mean a worse outcome).

    4. Accuracy of early rule out for myocardial infarction according to chest pain score (GRACE) [30 days]

      Accuracy of the 0 and 1 hour algorithm using troponin for diagnosis of myocardial infarction compared to the gold standard with measurements every 3 hours according to chest pain score (GRACE). GRACE score minimum 1 and maximum 372 points (higher scores mean a worse outcome).

    5. Accuracy of early rule out for myocardial infarction according to chest pain score (HEART) [30 days]

      Accuracy of the 0 and 1 hour algorithm using troponin for diagnosis of myocardial infarction compared to the gold standard with measurements every 3 hours according to chest pain score (HEART). HEART score minimum 0 and maximum 10 points (higher scores mean a worse outcome).

    6. Evaluation of the prognostic value (death and myocardial infarction within 30 days) of an isolated high-sensitivity cardiac troponin T < 5 ng/L in a diverse population. [30 days]

      Evaluation of the prognostic value (death and myocardial infarction within 30 days) of an isolated high-sensitivity cardiac troponin T < 5 ng/L in a diverse population (retrospective cohort).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age ≥ 18 years of age

    • The patient agrees and signs an informed consent form

    • One of the following 2 criteria:

    1. Acute chest pain (last episode of pain beginning <6 hours after inclusion) or

    2. Syncope, dyspnea or epigastric pain without an obvious cause at the initial assessment (last episode of one of these symptoms beginning <6 hours after inclusion) associated with at least one of the following factors: Age ≥ 65 years, history of arterial disease, history of diabetes mellitus.

    Exclusion Criteria:
    • Cardiac arrest or hypoxemia or hemodynamic instability or cardioversion during the first hour of assessment

    • Thrombolytic therapy, primary angioplasty or other medical condition that requires hospitalization identified within one hour after the evaluation

    • Dialysis patients

    • Patients with trauma

    • Myocardial revascularization or acute myocardial infarction in the last month

    • Pregnant and breastfeeding women

    • Patient unable to be followed for 30 days

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Samaritano Paulista São Paulo Brazil

    Sponsors and Collaborators

    • Hospital Samaritano Paulista
    • Roche Diagnostics

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Pedro Gabriel Melo de Barros e Silva, Principal Investigator, Hospital Samaritano Paulista
    ClinicalTrials.gov Identifier:
    NCT04756362
    Other Study ID Numbers:
    • 001/20
    First Posted:
    Feb 16, 2021
    Last Update Posted:
    Aug 3, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Pedro Gabriel Melo de Barros e Silva, Principal Investigator, Hospital Samaritano Paulista
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 3, 2022